Xenon Pharmaceuticals (NASDAQ:XENE) Research Coverage Started at Guggenheim

Guggenheim initiated coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE) in a research report report published on Friday, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $25.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Zacks Investment Research raised shares of Xenon Pharmaceuticals from a sell rating to a hold rating and set a $11.00 target price on the stock in a report on Thursday, August 8th. BidaskClub cut shares of Xenon Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, June 11th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Xenon Pharmaceuticals presently has an average rating of Buy and a consensus target price of $18.00.

Shares of NASDAQ XENE opened at $9.40 on Friday. The company has a quick ratio of 11.07, a current ratio of 11.07 and a debt-to-equity ratio of 0.18. The firm’s 50-day moving average price is $9.21 and its two-hundred day moving average price is $9.53. Xenon Pharmaceuticals has a 52-week low of $5.41 and a 52-week high of $13.70. The stock has a market capitalization of $237.90 million, a P/E ratio of -7.07 and a beta of 1.33.



Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.46) by $0.09. As a group, equities research analysts expect that Xenon Pharmaceuticals will post -1.88 earnings per share for the current year.

In other news, Director Frank A. Holler sold 5,069 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $9.32, for a total transaction of $47,243.08. Following the sale, the director now owns 136,129 shares of the company’s stock, valued at $1,268,722.28. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Holler sold 7,600 shares of Xenon Pharmaceuticals stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $9.27, for a total value of $70,452.00. Following the sale, the director now directly owns 124,161 shares in the company, valued at approximately $1,150,972.47. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 12,692 shares of company stock worth $117,909. Corporate insiders own 8.35% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its holdings in shares of Xenon Pharmaceuticals by 8.8% during the second quarter. Point72 Asset Management L.P. now owns 925,000 shares of the biopharmaceutical company’s stock valued at $9,121,000 after buying an additional 75,000 shares during the last quarter. Sphera Funds Management LTD. raised its holdings in shares of Xenon Pharmaceuticals by 18.7% during the first quarter. Sphera Funds Management LTD. now owns 533,655 shares of the biopharmaceutical company’s stock valued at $5,422,000 after buying an additional 84,171 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Xenon Pharmaceuticals by 0.7% during the second quarter. Renaissance Technologies LLC now owns 475,500 shares of the biopharmaceutical company’s stock valued at $4,688,000 after buying an additional 3,200 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $2,244,000. Finally, NEA Management Company LLC bought a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $1,802,000. 68.20% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Featured Story: Limitations to arbitrage trading

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.